1. Fakhouri F, Zuber J, V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017 Aug 12; 390(10095): 681 - 696. doi: 10.1016/S0140-6736(17)30062-4. Epub 2017 Feb 25. Erratum in: Lancet. 2017 Aug 12; 390(10095): 648. PMID: 28242109.

2. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008 Oct; 23(10): 1749 - 60. doi: 10.1007/s00467-008-0935-6. Epub 2008 Aug 13. PMID: 18704506; PMCID: PMC6901419.

3. Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018 Feb 7; 13(2): 300 - 317. doi: 10.2215/CJN.00620117. Epub 2017 Oct 17. PMID: 29042465; PMCID: PMC5967417.

4. Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am. 2017 Mar; 101(2): 395 - 415. doi: 10.1016/j.mcna.2016.09.010. Epub 2016 Dec 27. PMID: 28189178.

5. Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol. 2014 Jul; 36(4): 399 - 420. doi: 10.1007/s00281-014-0416-x. Epub 2014 Feb 14. PMID: 24526222.

6. Williams DM, Sreedhar SS, Mickell JJ, Chan JC. Acute kidney failure: a pediatric experience over 20 years. Arch Pediatr Adolesc Med. 2002 Sep; 156(9): 893 - 900. doi: 10.1001/archpedi.156.9.893. PMID: 12197796.

7. Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel). 2020 Jan 21; 12(2): 67. doi: 10.3390/toxins12020067. PMID: 31973203; PMCID: PMC7076748.

8. Луара Ш. Гемолитико-уремический синдром. В кн: Детская нефрология. Практическое руководство. Под ред. Э. Лойманна, А.Н. Цыгина и А.А. Саркисяна. - М.: Литтерра, 2010. - 400 с.

9. Ardissino G, Salardi S, Colombo E, et al. Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network. Eur J Pediatr. 2016 Apr; 175(4): 465 - 73. doi: 10.1007/s00431-015-2642-1. Epub 2015 Oct 24. PMID: 26498648.

10. Majowicz SE, Scallan E, Jones-Bitton A, Sargeant JM, Stapleton J, Angulo FJ, Yeung DH, Kirk MD. Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. Foodborne Pathog Dis. 2014 Jun; 11(6): 447 - 55. doi: 10.1089/fpd.2013.1704. Epub 2014 Apr 21. PMID: 24750096; PMCID: PMC4607253.

11. Kemper MJ. Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol. 2012 Feb; 27(2): 161 - 4. doi: 10.1007/S00467-011-2067-7. Epub 2011 Dec 13. PMID: 22160440.

12. Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, S, Bordes C, Reffet A, Llanas B, Skopinski S, Rolland P, Gruson D, Combe C Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant. 2014 Mar; 29(3): 565 - 72. doi: 10.1093/ndt/gft470. Epub 2013 Nov 28. PMID: 24293658; PMCID: PMC3938298.

13. Vaillant V, E, de Valk H, Durr U, Barataud D, Bouvet P, Grimont F, Desenclos JC. Undercooked ground beef and person-to-person transmission as major risk factors for sporadic hemolytic uremic syndrome related to Shiga-toxin producing Escherchia coli infections in children in France. Pediatr Infect Dis J. 2009 Jul; 28(7): 650 - 3. doi: 10.1097/INF.0b013e3181993731. PMID: 19483660.

14. Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol. 2010 Nov; 25(11): 2231 - 40. doi: 10.1007/s00467-010-1522-1. Epub 2010 Apr 28. PMID: 20424866.

15. Byrne L, Vanstone GL, Perry NT, Launders N, Adak GK, Godbole G, Grant KA, Smith R, Jenkins C. Epidemiology and microbiology of Shiga toxin-producing Escherichia coli other than serogroup O157 in England, 2009 - 2013. J Med Microbiol. 2014 Sep; 63(Pt 9): 1181 - 1188. doi: 10.1099/jmm.0.075895-0. Epub 2014 Jun 13. PMID: 24928216.

16. Tesh VL. Induction of apoptosis by Shiga toxins. Future Microbiol. 2010 Mar; 5(3): 431 - 53. doi: 10.2217/fmb.10.4. PMID: 20210553; PMCID: PMC2855686.

17. Gonzalo Ezequiel Pineda, Rearte, Florencia Todero, Andrea Cecilia Bruballa, Alan Mauro Bernal, Romina Jimena Fernandez-Brando, Martin Amadeo Isturiz, Elsa Zotta, Catalina Dirney Alba-Soto, Marina Sandra Palermo, Victoria Ramos. Absence of interleukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome. Clin Sci (Lond) 2021 Feb 12; 135(3): 575 - 588. doi: 10.1042/CS20200468.

18. Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med. 2017 Feb; 281(2): 123 - 148. doi: 10.1111/joim.12546. Epub 2016 Oct 10. PMID: 27723152.

19. Locatelli M, Buelli S, Pezzotta A, Corna D, Perico L, Tomasoni S, Rottoli D, Rizzo P, Conti D, Thurman JM, Remuzzi G, Zoja C, Morigi M. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol. 2014 Aug; 25(8): 1786 - 98. doi: 10.1681/ASN.2013050450. Epub 2014 Feb 27. PMID: 24578132; PMCID: PMC4116050.

20. AL, Sartz L, Nelsson A, ZD, Karpman D. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One. 2009 Sep ll; 4(9): e6990. doi: 10.1371/journal.pone.0006990. PMID: 19750223; PMCID: PMC2735777.

21. Butler T. Haemolytic uraemic syndrome during shigellosis. Trans R Soc Trop Med Hyg. 2012 Jul; 106(7): 395 - 9. doi: 10.1016/j.trstmh.2012.04.001. Epub 2012 May 10. PMID: 22579556.

22. Kampmeier S, Berger M, Mellmann A, Karch H, Berger P. The 2011 German Enterohemorrhagic Escherichia Coli O104:H4 Outbreak - The Danger Is Still Out There. Curr Top Microbiol Immunol. 2018; 416: 117 - 148. doi: 10.1007/82_2018_107. PMID: 30062592.

23. Bruyand M, Mariani-Kurkdjian P, Le Hello S, King LA, Van Cauteren D, Lefevre S, Gouali M, Jourdan-da Silva N, Mailles A, Donguy MP, Loukiadis E, Sergentet-Thevenot D, Loirat C, Bonacorsi S, Weill FX, De Valk H; Hospitalier de Surveillance du Shu . Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Escherichia coli, an overview of 10 years of surveillance in France, 2007 to 2016. Euro Surveill. 2019 Feb; 24(8): 1800068. doi: 10.2807/1560-7917.ES.2019.24.8.1800068. PMID: 30808442; PMCID: PMC6446949.

24. Miquel Blasco, Elena , Luis F Quintana, Adriana Garcia-Herrera, , Esteban Poch, Enric Carreras, Josep M Campistol, Maribel Diaz-Ricart, Marta Palomo, Thrombotic microangiopathies assessment: mind the complement, Clinical Kidney Journal, 2020; sfaa195, https://doi.org/10.1093/ckj/sfaa195.

25. Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017 Jan 30; 189(4): E153 - E159. doi: 10.1503/cmaj.160142. Epub 2016 Oct 17. PMID: 27754896; PMCID: PMC5266569.

26. Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis. 2019 Sep 4; 12: 183 - 204. doi: 10.2147/IJNRD.S215370. PMID: 31564951; PMCID: PMC6732511.

27. Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res. 2019 Sep 25; 8: F1000 Faculty Rev-1690. doi: 10.12688/f1000research.19957.1. PMID: 31598213; PMCID: PMC6764117.

28. Ariceta G. Hemolytic Uremic Syndrome. December 2020; Current Treatment Options in Pediatrics 6(4): 252 - 262. DOI: 10.1007/s40746-020-00216-1.

29. Goodship TH: Factor H genotype-phenotype correlations: Lessons from aHUS, MPGN II, and AMD. Kidney Int. 2006; 70(1): 12 - 3.

30. Jokiranta TS. HUS and atypical HUS. Blood. 2017 May 25; 129(21): 2847 - 2856. doi: 10.1182/blood-2016-11-709865. Epub 2017 Apr 17. PMID: 28416508; PMCID: PMC5445567.

31. RA, Tagle R, Jara A. [Atypical hemolytic uremic syndrome]. Rev Med Chil. 2018 Jun; 146(6): 770 - 779. Spanish, doi: 10.4067/s0034-98872018000600770. PMID: 30148909.

32. Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ. Atypical aHUS: State of the art. Mol Immunol. 2015 Sep; 67(1): 31 - 42. doi: 10.1016/j.molimm.2015.03.246. Epub 2015 Apr 3. PMID: 25843230.

33. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010 Oct; 5(10): 1844 - 59. doi: 10.2215/CJN.02210310. Epub 2010 Jul 1. PMID: 20595690; PMCID: PMC2974386.

34. Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, JM, Praga M, Torra R, Vilalta R, S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2013 Jan 18; 33(1): 27 - 45. English, Spanish, doi: 10.3265/Nefrologia.pre2012.Nov.11781. PMID: 23364625.

35. Loirat C, Fakhouri F, Ariceta G, et al; HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016 Jan; 31(1): 15 - 39. doi: 10.1007/s00467-015-3076-8. Epub 2015 Apr 11. PMID: 25859752.

36. Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review. Clin Epidemiol. 2020 Mar 12; 12: 295 - 305. doi: 10.2147/CLEP.S245642. PMID: 32210633; PMCID: PMC7075343.

37. Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM. Etiology and Outcomes of Thrombotic Microangiopathies. Clin J Am Soc Nephrol. 2019 Apr 5; 14(4): 557 - 566. doi: 10.2215/CJN.11470918. Epub 2019 Mar 12. PMID: 30862697; PMCID: PMC6450353.

38. Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey MA; Indian Society of Pediatric Nephrology. Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatr Nephrol. 2019 Aug; 34(8): 1465 - 1482. doi: 10.1007/s00467-019-04233-7. Epub 2019 Apr 15. PMID: 30989342.

39. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J. 2019 Apr 21; 12(3): 333 - 337. doi: 10.1093/ckj/sfz040. PMID: 31198225; PMCID: PMC6543965.

40. Thayu M, Chandler WL, Jelacic S, et al. Cardiac ischemia during hemolytic uremic syndrome. Pediatr Nephrol. 2003 Mar; 18(3): 286 - 9. doi: 10.1007/s00467-002-1039-3. Epub 2003 Feb 7. PMID: 12644926.

41. Thomas NJ, Messina JJ, DeBruin WJ, Carcillo JA. Cardiac failure in hemolytic uremic syndrome and rescue with extracorporeal life support. Pediatr Cardiol. 2005 Jan-Feb; 26(1): 104 - 6. doi: 10.1007/s00246-004-0708-3. PMID: 15136901.

42. Шпикалова И.Ю. Панкратенко Т.Е. Эмирова Х.М. Зверев Д.В. Толстова Е.М. Поражение ЦНС у больных с Шига-токсин ассоциированным гемолитико-уремическим синдромом (STEC-ГУС): современные аспекты патогенеза, клиники и стратегии лечения (Обзор литературы) Нефрология и диализ, 2014; 16(3): 328 - 338.

43. Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol. 2012 Nov; 8(ll): 658 - 69. doi: 10.1038/nrneph.2012.196. Epub 2012 Sep 18. PMID: 22986362.

44. Suri RS, Clark WF, Barrowman N, Mahon JL, Thiessen-Philbrook HR, Rosas-Arellano MP, Zarnke K, Garland JS, Garg AX. Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis. Diabetes Care. 2005 Oct; 28(10): 2556 - 62. doi: 10.2337/diacare.28.10.2556. PMID: 16186301.

45. Suri RS, Mahon JL, Clark WF, et al. Relationship between Escherichia coli O157:H7 and diabetes mellitus. Kidney Int Suppl. 2009 Feb; (112): S44 - 6. doi: 10.1038/ki.2008.619. PMID: 19180134.

46. Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol. 2014 Mar; 10(3): 174 - 80. doi: 10.1038/nrneph.2013.280. Epub 2014 Jan 14. PMID: 24419569.

47. Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol. 2019 Aug; 34(8): 1337 - 1348. doi: 10.1007/s00467-018-4039-7. Epub 2018 Aug 14. PMID: 30109445.

48. Loirat C, Macher MA, Elmaleh-Berges M, Kwon T, Deschenes G, Goodship TH, Majoie C, Davin JC, Blanc R, Savatovsky J, Moret J, Fremeaux-Bacchi V. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant. 2010 Oct; 25(10): 3421 - 5. doi: 10.1093/ndt/gfq319. Epub 2010 Jun 8. PMID: 20530807.

49. Sampedro Lopez A, Dominguez Moro B, Baltar Martin JM et al. Ocular involvement in atypical hemolytic uremic syndrome. Arch Soc Esp Oftalmol. 2017; 92(12): 594 - 597. https://doi.org/10.1016/j.oftal.2017.02.007.

50. Ardissino G, Tel F, Testa S, Marzano AV, Lazzari R, Salardi S, Edefonti A. Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis. 2014 Apr; 63(4): 652 - 5. doi: 10.1053/j.ajkd.2013.09.020. Epub 2013 Nov 27. PMID: 24290245.

51. Al-Ahmad M, Kharita L, Wannous H. Atypical hemolytic uremic syndrome with peripheral gangrene and homocysteinemia in a child. Oxf Med Case Reports. 2020 Jul 24; 2020(7): omaa048. doi: 10.1093/omcr/omaa048. PMID: 32728451; PMCID: PMC7376982.

52. Hervent AS, Godefroid M, Cauwelier B, Billiet J, Emmerechts J. Evaluation of schistocyte analysis by a novel automated digital cell morphology application. Int J Lab Hematol. 2015 Oct; 37(5): 588 - 96. doi: 10.1111/ijlh.12363. Epub 2015 Apr 28. PMID: 25923397.

53. Scobell RR, Kaplan BS, Copelovitch L. New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol. 2020 Sep; 35(9): 1585 - 1591. doi: 10.1007/s00467-019-04342-3. Epub 2019 Sep 13. PMID: 31515631.

54. Holle J, Habbig S, Gratopp A, Mauritsch A, D, Thumfart J. Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome. Pediatr Nephrol. 2021 May; 36(5): 1311 - 1315. doi: 10.1007/s00467-021-04952-w. Epub 2021 Feb 4. PMID: 33538911.

55. Bitzan M, AlKandari O, Whittemore B, Yin XL. Complement depletion and Coombs positivity in pneumococcal hemolytic uremic syndrome (pnHUS). Case series and plea to revisit an old pathogenetic concept. Int J Med Microbiol. 2018 Dec; 308(8): 1096 - 1104. doi: 10.1016/j.ijmm.2018.08.007. Epub 2018 Aug 29. PMID: 30177469.

56. Johnson S, Waters A. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? Immunobiology. 2012 Feb; 217(2): 235 - 43. doi: 10.1016/j.imbio.2011.07.022. Epub 2011 Jul 26. PMID: 21852019.

57. Koenig JC, Rutsch F, Bockmeyer C, Baumgartner M, Beck BB, Kranz B, Konrad M. Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency. Pediatr Nephrol. 2015 Jul; 30(7): 1203 - 6. doi: 10.1007/s00467-015-3110-x. Epub 2015 Apr 18. PMID: 25894566.

58. S, Bekri S, Artaud-Macari E, Francois A, Girault C, Poitou AL, Benhamou Y, Vianey-Saban C, Benoist JF, V, Tamion F, Guerrot D. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet. 2015 Sep 5; 386(9997): 1011 - 2. doi: 10.1016/S0140-6736(15)00076-8. PMID: 26369474.

59. Резолюция экспертного совета по оптимизации подходов к терапии атипичного гемолитико-уремического синдрома по итогам заседания 18 апреля 2014 года, г. Москва Нефрология и диализ, 2014 год; 16(2): 304 - 306.

60. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, V, Kavanagh D, Nester CM, Noris M, Pickering MC, S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017 Mar; 91(3): 539 - 551. doi: 10.1016/j.kint.2016.10.005. Epub 2016 Dec 16. PMID: 27989322.

61. Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012 Oct; 10(10 Suppl 17): 1 - 12. PMID: 23187605.

62. Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, , Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, V; Global aHUS Registry. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018 Aug; 94(2): 408 - 418. doi: 10.1016/j.kint.2018.02.029. Epub 2018 Jun 19. PMID: 29907460.

63. Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020 Jan; 35(1): 25 - 40. doi: 10.3904/kjim.2019.388. Epub 2020 Jan 2. PMID: 31935318; PMCID: PMC6960041.

64. Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, Grovetto E, Possenti I, Perrone M, Testa S, Paglialonga F, Messa P, Cugno M. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 2018 Mar; 33(3): 457 - 461. doi: 10.1007/s00467-017-3813-2. Epub 2017 Oct 18. PMID: 29046944.

65. Balestracci, A.; Martin, S.M.; Toledo, I.; Alvarado, C; Wainsztein, R.E. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr. Nephrol. 2012, 27, 1407 - 1410

66. Ariceta, G. Hemolytic Uremic Syndrome. Curr Treat Options Peds 6, 252 - 262 (2020). https://doi.org/10.1007/s40746-020-00216-1

67. Kato H, Nangaku M, Hataya H, et al; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016 Aug; 20(4): 536 - 543

68. Medscape, Pediatric Hemolytic Uremic Syndrome Workup, Updated: Nov 12, 2018 Author: Robert S Gillespie et al. https://emedicine.medscape.com/article/982025-workup

69. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005; 16: 1035 - 50

70. Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child. 2018 Mar; 103(3): 285 - 291

71. Loirat C et al. Hemolytic-uremic syndrome: an analysis of the natural history and prognostic features//Acta . - 1984. - T. 73. - N. 4. - С. 505 - 514\

72. Geerdink L.M. et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics//Pediatric Nephrology. - 2012. - T. 27. - N. 8. - С. 1283 - 1291

73. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013 Apr; 8(4): 554 - 62

74. Mallett A, Hughes P, Szer J, et al. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J. 2015 Oct; 45(10): 1054 - 65

75. Shimizu M, Inoue N, Kuroda M, et al. Serum ferritin as an indicator of the development of encephalopathy in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Clin Exp Nephrol. 2017 Dec; 21(6): 1083 - 1087

76. Basak R, Wang X, Keane C, Woroniecki R. Atypical presentation of atypical haemolytic uraemic syndrome. BMJ Case Rep. 2018 Feb 11; 2018: bcr2017222560

77. Kamioka I, Yoshiya K, Satomura K, et al; Japanese Society for Pediatric Nephrology. Risk factors for developing severe clinical course in HUS patients: a national survey in Japan. Pediatr Int. 2008 Aug; 50(4): 441 - 6

78. Manrique-Caballero CL, Peerapornratana S, Formeck C, et al. Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. Crit Care Clin. 2020 Apr; 36(2): 333 - 356

79. Zervou S, Whittington HJ, Russell AJ, Lygate CA. Augmentation of Creatine in the Heart. Mini Rev Med Chem. 2016; 16(1): 19 - 28

80. Erickson YO, Samia NI, Bedell B, et al. Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients. J Clin Apher. 2009; 24(4): 150 - 4

81. Sivamurthy S, Mooney JD, Kenny TD. Atypical haemolytic uraemic syndrome presenting initially as suspected meningococcal disease: a case report. J Med Case Rep. 2007 Oct 30; 1: 122

82. Goffin L, Lolin K, Janssen F, Schurmans T, Dorchy H. Insulin-dependent diabetes mellitus as long term complication of haemolytic-uraemic syndrome. Diabetes Metab. 2006 Jun; 32(3): 276 - 8

83. N, AS, Dursun , Yel S, MH, R. A child with anemia, thrombocytopenia, renal failure and elevated amylase, and lipase enzymes: Answers. Pediatr Nephrol. 2019 Jul; 34(7): 1219 - 1221

84. Sohaib K Mohammed, Ateeq Mubarik, Bilal Nadeem, Khudadad Khan, and Salman Muddassir Atypical Hemolytic Uremic Syndrome: A Case ReportCureus. 2019 May; 11(5): e4634

85. Chang HJ, Kim HY, Choi JH, Choi HJ, Ko JS, Ha IS, Cheong HI, Choi Y, Kang HG. Shiga toxin-associated hemolytic uremic syndrome complicated by intestinal perforation in a child with typical hemolytic uremic syndrome. Korean J Pediatr. 2014 Feb; 57(2): 96 - 9, https://bestpractice.bmj.com/topics/en-gb/470

86. Cheong HI, Jo SK, Yoon SS, et al. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci. 2016 Oct; 31(10): 1516 - 28

87. Thurman JM. Complement Biomarkers of Hemolytic Uremic Syndrome - If Not One Thing, Maybe Another. Mayo Clin Proc. 2018 Oct; 93(10): 1337 - 1339

88. Westra D. et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome//Pediatric Nephrology. - 2017. - T. 32. - N. 2. - С. 297 - 309.

89. Loirat C, Noris M., Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children//Pediatric nephrology. - 2008. - T. 23. - N. 11. - С 1957 - 1972.

90. Wada H, Matsumoto T, Suzuki K, et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018 Jul 11; 16: 14

91. Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep. 2021 Jan; 6(1): 11 - 23

92. Zini G, De Cristofaro R. Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies. Turk J Haematol. 2019 Nov 18; 36(4): 222 - 229

93. Iba T., Levy J.H., Wada H., et al. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J. Thromb. Haemost. 2019; 17(2): 415 - 419

94. Harahsheh Y, Ho KM. Thromboelastometry and thromboelastography failed to detect hypercoagulability in thrombotic microangiopathy. Anaesth Intensive Care. 2016 Jul; 44(4): 520 - 1

95. Rigamonti D, Simonetti GD. Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature. Eur J Pediatr. 2016 Dec; 175(12): 1927 - 1931

96. Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barratt TM. Long term renal outcome of childhood haemolytic uraemic syndrome. BMJ. 1991 Aug 31; 303(6801): 489 - 92

97. Karmali MA, Petric M, Bielaszewska M. Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and characterizing verotoxins (Shiga toxins) in Escherichia coli. J Clin Microbiol. 1999 Feb; 37(2): 396 - 9.

98. Fox LC, Cohney SJ, Kausman JY, et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Intern Med J. 2018 Jun; 48(6): 624 - 636

99. Baumgartner, M.R., , F., Dionisi-Vici, C et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis 9, 130 (2014). https://doi.org/10.1186/s13023-014-0130-8

100. С.В. Михайлова, Е.Ю. Захарова, А.С. Петрухин: Нейрометаболические заболевания у детей и подростков. Диагностика и подходы к лечению. Москва, издательство "Литтерра" 2019, 34 - 36 с.

101. Sharma AP, Greenberg CR, Prasad AN, Prasad C. Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol. 2007 Dec; 22(12): 2097 - 103,

102. Huemer M, Diodato D, Schwahn B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017 Jan; 40(1): 21 - 48

103. Chen M, Zhuang J, Yang J, et al. Atypical hemolytic uremic syndrome induced by CblC subtype of methylmalonic academia: A case report and literature review. Medicine (Baltimore). 2017 Oct; 96(43): e8284. doi: 10.1097/MD.0000000000008284. PMID: 29068997; PMCID: PMC5671830

104. Laurence J., Haller H., Mannucci P.M., et al. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin. Adv. Hematol. Oncol. 2016; 14 Suppl. 11(11): 2 - 15

105. Medscape, Pediatric Hemolytic Uremic Syndrome Updated: Nov 12, 2018 Author: Robert S Gillespie, https://emedicine.medscape.com/article/982025-workup28

106. Proesmans W, D"Hooge A, Van Dyck M, Van Geet C. thrombophilia in childhood hemolytic uremic syndrome. Pediatr Nephrol. 2002 Aug; 17(8): 699 - 700

107. Ueda Y, Miwa T, Gullipalli D, et al. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia. J Am Soc Nephrol. 2018 Jul; 29(7): 1928 - 1937

108. B, D, R, et al. Long-term follow-up of children with typical hemolytic uremic syndrome. Medicina (Kaunas). 2015; 51(3): 146 - 151

109. Togarsimalemath SK, Si-Mohammed A, Puraswani M, et al. Gastrointestinal pathogens in anti-FH antibody positive and negative Hemolytic Uremic Syndrome. Pediatr Res. 2018 Jul; 84(1): 118 - 124

110. Imataka G, Wake K, Suzuki M, et al. Acute encephalopathy associated with hemolytic uremic syndrome caused by Escherichia coli O157:H7 and rotavirus infection. Eur Rev Med Pharmacol Sci. 2015 May; 19(10): 1842 - 4

111. Birlutiu V, Birlutiu RM. Haemolytic-uremic syndrome due to infection with adenovirus: A case report and literature review. Medicine (Baltimore). 2018 Feb; 97(7): e9895

112. Reising A, Hafer C, Hiss M, et al. Ultrasound findings in EHEC-associated hemolytic-uremic syndrome and their clinical relevance. Int Urol Nephrol. 2016 Apr; 48(4): 561 - 70

113. Abrams CM, Hijano DR, Bagga B. Abdominal Pain in the Setting of Atypical Hemolytic Uremic Syndrome Caused by Streptococcus pneumoniae Pneumonia. Glob Pediatr Health. 2018 Mar 8; 5: 2333794X18762866/

114. Koehl B. et al. Neurological involvement in a child with atypical hemolytic uremic syndrome//Pediatric nephrology. - 2010. - T. 25. - N. 12. - С. 2539 - 2542

115. Toldo I. et al. Diffusion-weighted imaging findings in hemolytic uremic syndrome with central nervous system involvement//Journal of child neurology. - 2009. - T. 24. - N. 2. - С. 247 - 250

116. Eriksson KJ, Boyd SG, Tasker RC. Acute neurology and neurophysiology of haemolytic-uraemic syndrome. Arch Dis Child. 2001 May; 84(5): 434 - 5

117. Lucas J. Rindy; Aaron R. Chambers. Bone Marrow Aspiration And Biopsy Treasure Island (FL): StatPearls Publishing; 2021 Jan - https://www.ncbi.nlm.nih.gov/books/NBK559232/

118. Bain BJ. Bone marrow aspiration. J Clin Pathol. 2001 Sep; 54(9): 657 - 63

119. Medscape, https://emedicine.medscape.com/article/982025-overview

120. Scully M, Cataland S, Coppo P, et al; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 Feb; 15(2): 312 - 322. doi: 10.1111/jth.13571. Epub 2017 Jan 30. PMID: 27868334.

121. Campbell CM, Kahwash R (2020) Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis. Circulation 141: 1739 - 1741

122. Ramlall V, Thangaraj P, Meydan C et al (2020) Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. https://doi.org/10.1058/s41591-020-1021-2

123. Wang X, Sahu KK, Cerny J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb Thrombolysis. 2021 Apr; 51(3): 657 - 662. doi: 10.1007/s11239-020-02297-z. Epub 2020 Oct 15. PMID: 33063256; PMCID: PMC7561230

124. Kellum, J.A.; Lameire, N.; Aspelin, P., et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2012, 2, 1 - 138

125. Ake, J.A., Jelacic, S., Ciol, M.A., et al. Relative Nephroprotection During Escherichia coli O157:H7 Infections: Association With Intravenous Volume Expansion. Pediatrics 2005, 115, e673 - e680

126. Grisaru, S.; Xie, J.; Samuel, S.; et al; Alberta Provincial Pediatric Enteric Infection Team. Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin-Producing Escherichia coli: A Systematic Review and Meta-analysis. JAMA Pediatr. 2017, 171, 68 - 76

127. Ardissino, G.; Tel, F.; Possenti, I.; et al. Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome. Pediatrics 2016, 137, e20152153

128. Reintam Blaser, A.; Starkopf, J.; Alhazzani, W.; et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive Care Med. 2017, 43, 380 - 398

129. https://www.sciencedirect.com/topics/medicine-and-dentistrv/hemorrhagic-colitis

130. Medscape, Pediatric Escherichia Coli Infections Treatment & Management https://emedicine.medscape.com/article/970451-treatment

131. Cimolai, N.; Basalyga, S.; Mah, D.G.; Morrison, B.J.; Carter, J.E. A continuing assessment of risk factors for the development of Escherichia coli O157:H7 - associated hemolytic uremic syndrome. Clin. Nephrol. 1994, 42, 85 - 89

132. Nelson JM, Griffin PM, Jones TF, Smith KE, Scallan E. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites. Clin Infect Dis. 2011 May; 52(9): 1130 - 2. doi: 10.1093/cid/cir087. PMID: 21467017

133. Kimmitt, P.T.; Harwood, C.R.; Barer, M.R. Toxin gene expression by shiga toxin-producing Escherichia coli: The role of antibiotics and the bacterial SOS response. Emerg. Infect. Dis. 2000, 6, 458 - 465

134. Wong, C.S.; Mooney, J.C.; Brandt, J.R.; Staples, A.O.; Jelacic, S.; Boster, D.R.; Watkins, S.L.; Tarr, P.I. Risk Factors for the Hemolytic Uremic Syndrome in Children Infected With Escherichia coli O157:H7: A Multivariable Analysis. Clin. Infect. Dis. 2012, 55, 33 - 41

135. Harkins, V.J., McAllister, D.A. & Reynolds, B.C. Shiga-Toxin E. coli Hemolytic Uremic Syndrome: Review of Management and Long-term Outcome. Curr Pediatr Rep 8, 16 - 25 (2020). https://doi.org/10.1007/s40124-020-00208-7

136. Lane RD, Olson J, Reeder R, Miller B, Workman JK, Thorell EA, Larsen GY. Antibiotic Timing in Pediatric Septic Shock. Hosp Pediatr. 2020 Apr; 10(4): 311 - 317

137. Medscape, Pediatric Hemolytic Uremic Syndrome Updated: Nov 12, 2018 https://emedicine.medscape.com/article/982025-treatment

138. Rizzoni, G.; Claris-Appiani, A.; Edefonti, A.; et al. Plasma infusion for hemolytic-uremic syndrome in children: Results of a multicenter controlled trial. J. Pediatr. 1988, 112, 284 - 290.

139. Lu J, Zhang L, Xia C, Tao Y. Complications of therapeutic plasma exchange: A retrospective study of 1201 procedures in 435 children. Medicine (Baltimore). 2019 Dec; 98(50): e18308

140. Jean J. Filipov, Borelli K. Zlatkov and Emil P. Dimitrov (May 16th 2018). Plasma Exchange in Clinical Practice, Plasma Medicine - Concepts and Clinical Applications, Yusuf Tutar and Lutfi Tutar, IntechOpen, DOI: 10.5772/intechopen.76094. Available from: https://www.intechopen.com/chapters/60542

141. Filip C, Nicolescu A, Cinteza E, et al. Cardiovascular Complications of Hemolytic Uremic Syndrome in Children. Maedica (Bucur). 2020 Sep; 15(3): 305 - 309

142. , C; , F.; Alvarez-Moreno, A.; et al; Castro-Gago, M. Reversible posterior leukoencephalopathy syndrome: An infrequent complication in the course of haemolytic-uremic syndrome. Rev. Neurol. 2007, 44, 475 - 478

143. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease - a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011 Dec; 80(11): 1122 - 37

144. Smyth B, Jones C, Saunders J. Prescribing for patients on dialysis. Aust Prescr. 2016 Feb; 39(1): 21 - 4. doi: 10.18773/austprescr.2016.008

145. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2: 1 - 138

146. Medscape, Pediatric Hemolytic Uremic Syndrome Medication Updated: Nov 12, 2018, https://emedicine.medscape.com/article/982025-medication#showall

147. Perez, N.; Spizzirri, F.; Rahman, R.; Suarez, A.; Larrubia, C; Lasarte, P. Steroids in the hemolytic uremic syndrome. Pediatr. Nephrol. 1998, 12, 101 - 104

148. Menne J, Nitschke M, Stingele R, et al; EHEC-HUS consortium. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ. 2012 Jul 19; 345: e4565

149. Michael M, Elliott EJ, Craig JC, et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009 Feb; 53(2): 259 - 72

150. Robitaille P, Clermont MJ, A, Phan V, Lapeyraque AL. Hemolytic uremic syndrome: late renal injury and changing incidence - a single centre experience in Canada. Scientifica (Cairo). 2012; 2012: 341860. doi: 10.6064/2012/341860

151. Dyck, M.V.; Proesmans, W. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr. Nephrol. 2004, 19, 688 - 690

152. Caletti MG, Balestracci A, Missoni M, Vezzani C Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome. Pediatr Nephrol. 2013 May; 28(5): 745 - 50. doi: 10.1007/s00467-012-2374-7. Epub 2012 Dec 20. PMID: 23250713

153. Caletti MG, Missoni M, Vezzani C, et al. Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. Pediatr Nephrol. 2011 Aug; 26(8): 1247 - 54. doi: 10.1007/s00467-011-1867-0

154. Ito S, Hidaka Y, Inoue N, et al. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019 Jan; 23(1): 112 - 121

155. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368: 2169 - 2181. doi: 10.1056/NEJMoa1208981

156. Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of Eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015; 87: 1061 - 1073. doi: 10.1038/ki.2014.42

157. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of the atypical hemolytic uremic syndrome in chidren. Pediatr Nephrol 2016; 31(1): 15 - 39. doi: 10.1007/s00467-015-3076-8

158. Krishnappa V. et al. Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens//Therapeutic Apheresis and Dialysis. - 2018. - T. 22. - N. 2. - С. 178 - 188.

159. Menne J et al. Long-term safety and effectiveness of eculizumab for patients with atypical haemolytic uraemic syndrome: outcomes from a prospective observational clinical trial. Nephrol Dial Transplant (2017) 32 (suppl_3): iii572 - iii573. DOI: https://doi.org/10.1093/ndt/gfx170.MP3931

160. Menne J, Delmas Y, Fakhouri F, et al. Eculizumab prevents thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome in a long-term observational study. Clin Kidney J 2018; 12(2): 196 - 205. doi: 10.1093/ckj/sfy035

161. Puraswani M, Khandelwal P, Saini H, et al. Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Front Immunol. 2019 Jun 7; 10: 1282. doi: 10.3389/fimmu.2019.01282. PMID: 31231391; PMCID: PMC6567923

162. Boyer O, Balzamo E, Charbit M, et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis. 2010 May; 55(5): 923 - 7. doi: 10.1053/j.ajkd.2009.12.026

163. Complement-mediated hemolytic uremic syndrome in children https://www.uptodate.com/contents/complement-mediated-hemolytic-uremic-syndrome-in-children?search=Complement-mediated%20hemolytic%20uremic%20syndrome%20in%20children&source=search_result&select (last updated: Aug 30, 2021)

164. Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol. 2016 Sep; 12(9): 563 - 78. doi: 10.1038/nrneph.2016.99

165. Sinha A, Gulati A, Saini S, et al; Indian HUS Registry. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 2014 May; 85(5): 1151 - 60. doi: 10.1038/ki.2013.373.

166. Fakhouri F, Loirat C (2018) Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol 55: 150 - 158

167. Kise T, Fukuyama S, Uehara M. Successful Treatment of Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome. Indian J Nephrol. 2020 Jan - Feb; 30(1): 35 - 38. doi: 10.4103/ijn.IJN_336_1

168. ГРЛС https://grls.rosminzdrav.ru

169. Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021 May 6; 137(18): 2438 - 2449

170. Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018 Jun; 24 Suppl 2: S21 - S40

171. Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019 Nov; 34(11): 2261 - 2277

172. Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом**/Эпидемиология и Вакцинопрофилактика N 1 (92)/2017/ - С. 51 - 54

173. Методические рекомендации по вакцинопрофилактике пневмококковой инфекции у детей. М.: 2018. - 28 с

174. Treatment-and-prevention-of-meningococcal-infection https://www.uptodate.com/contents/treatment-and-prevention-of-meningococcal-infection? sectionName=Patients%20receiving%20C5%20inhibitors&search=atypical%20HUS%20children&

175. Tanaka K, Fujita N, Hibino S. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases. CEN Case Rep. 2020 Aug; 9(3): 247 - 251

176. McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Solids) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep. 2017 Jul 14; 66(27): 734 - 737

177. https://www.healio.com/news/infectious-disease/20180509/preventing-meningococcal-disease-in-patients-receiving-soliris

178. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62: 1

179. American Academy of Pediatrics. Meningococcal infections. In: Kimberlin DW, Jackson MA, Long SS, Brady MT (eds). Red Book: 2018 - 2021 Report of the Committee on Infectious Diseases. Itasca, IL: American Academy of Pediatrics; 2018: 550

180. Krone M et al. Susceptibility of invasive Neisseria meningitidis strains isolated in Germany to azithromycin, an alternative agent for post-exposure prophylaxis. J Antimicrob Chemother 2020 Jan 23; [e-pub]. (https://doi.org/10.1093/jac/dkz535), Atypical Hemolytic Uremic Syndrome (aHUS): Treating the Patient Clinical Advances in Hematology & Oncology Volume 11, Issue 10, Supplement 15 October 2013: 4 - 16

181. Козловская Н.Л., Прокопенко Е.И., Эмирова Х.М., Серикова С.Ю. Клинические рекомендации по диагностике и лечению атипичного гемолитико-уремического синдрома/Нефрология и диализ, 2015, том 17, N 3. - С. 242 - 264

182. Manuel Macia; Fernando de Alvaro Moreno, Tina Dutt, et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome Clin Kidney J. 2016, 1 - 10; doi: 10.1093/ckj/sfw115

183. Go RS, Winters JL, Leug N, et al. Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic complement alternative pathway - thrombotic microangiopathy (CAP-TMA) disease-oriented group//Mayo Clin Proc 2016; 91(9) 1189 - 1211. http://dx.doi.org./10.1016/j.mayocp.2016.05.015

184. Menne J, Delmas Y, Fakhouri F, et al. Outcome in patients with atypical hemolytic uremic syndrome treated with Eculizumab in a long-term observational study. BMC Nephrology 2019; 20: 125 - 137. https://doi.org/10.1186/s12882-019-1314-1

185. Fakhouri F, Fila M, F, et al. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol. 2017 Jan 6; 12(1): 50 - 59

186. Avila Bernabeu Al, Cavero Escribano T, Cao Vilarino M. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era. Nephron. 2020; 144(11): 537 - 549. doi: 10.1159/000508920. Epub 2020 Sep 18. PMID: 32950988.

187. Chaturvedi S, Dhaliwal N, Hussain S, et al. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv. 2021 Mar 9; 5(5): 1504 - 1512. doi: 10.1182/bloodadvances. 2020003175. PMID: 33683339; PMCID: PMC7948299

188. Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial. 2019 Feb; 23(1): 4 - 21. doi: 10.1111/1744-9987.12763. Epub 2018 Oct 29. PMID: 30294946

189. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB; European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009 Apr; 24(4): 687 - 96

190. Nods M, Bresin E, Mele C, Remuzzi G. Genetic Atypical Hemolytic-Uremic Syndrome. 2007 Nov 16 [updated 2016 Jun 9]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. [Internet]. Seattle (WA): University of Washington, Seattle; 1993 - 2021. PMID: 20301541

191. Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles. Clin J Am Soc Nephrol. 2018 Jul 6; 13(7): 1085 - 1095

192. Roberts DM, Sevastos J, Carland JE, Stocker SL, Lea-Henry TN. Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens. Clin J Am Soc Nephrol. 2018 Aug 7; 13(8): 1254 - 1263

193. Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, V, Niaudet P. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant. 2012; 12: 1938 - 44

194. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011; 26: 1325 - 9

195. Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006; 1: 88 - 99

196. Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne). 2014 Dec 12; 1: 52

197. Claes KJ, Massart A, Collard L, Weekers L, Goffin E, Pochet JMet al. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg 2018; 73: 80 - 89. http://doi.org/10.1080/17843286.2017.1345185

198. Каабак М.М., Молчанова Е.А., Нестеренко И.В., Пинчук А.В., Прокопенко Е.И., Столяревич Е.С., Сушков А.И., Томилина Н.А., Цыгин А.Н., Эмирова Х.М., Бабенко Н.Н. Резолюция Междисциплинарного совета экспертов. Трансплантация почки у пациентов с атипичным гемолитико-уремическим синдромом: клинические и организационно-методические аспекты ведения пациентов. Нефрология. 2018; 3: 8 - 14. doi: 10.18565/nephrology.2018.3.8-14

199. Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(7). pii: E919. doi: 10.3390/jcm8070919

200. Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ; Global aHUS Registry. Eculizumab use for kidney transplantation patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2018 Dec 3; 4(3): 434 - 446. doi: 10.1016/j.ekir.2018.11.010

201. Manuel Macia, Fernando de Alvaro Moreno, Tina Dutt, Ingela Fehrrnan, Karine Hadaya5, Christoph Gasteyger and Nils Heyne//Clinical Kidney Journal, 2016, 1 - 10, doi: 10.1093/clg/sfwll5.

202. Bonthuis M, Harambat J, E, Cransberg K, Duzova A, Garneata L, Herthelius M, Lungu AC, Jahnukainen T, Kaltenegger L, Ariceta G, Maurer E, Palsson R, Sinha MD, Testa S, Groothoff JW, Jager KJ; ESPN/ERA-EDTA Registry. Recovery of Kidney Function in Children Treated with Maintenance Dialysis. Clin J Am Soc Nephrol. 2018 Oct 8; 13(10): 1510 - 1516

203. Zhang K., Lu Y., Harley K.T., Tran M.H. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol. Rep. 2017; 9(2): 7053

204. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016 Jun 2; 2: 16037